Abstract
The natural products teleocidins, phorbol esters, asplysiatoxin, ingenol esters, and bryostatins are all potent protein kinase C (PKC) activators. The fact that they act at the same site of PKC implied that these structurally diverse molecules might contain the common structural elements. Several pharmacophores for these compounds have been proposed based on the molecular modeling studied and experimental results. In order to prove these hypotheses various simplified analogues of these compounds are designed, synthesized, and evaluated as new PKC activators. Some of the simplified analogues demonstrated much high potency to activate PKC, which not only gives some insights how these PKC activators bind with PKC, but also provides the new leads to develop the therapeutic tools to treat the diseases related by PKC.
Current Medicinal Chemistry
Title: Recent Advances in the Discovery of Protein Kinase C Modulators Based on the Structures of Natural Protein Kinase C Activators
Volume: 8 Issue: 2
Author(s): Dawei Ma
Affiliation:
Abstract: The natural products teleocidins, phorbol esters, asplysiatoxin, ingenol esters, and bryostatins are all potent protein kinase C (PKC) activators. The fact that they act at the same site of PKC implied that these structurally diverse molecules might contain the common structural elements. Several pharmacophores for these compounds have been proposed based on the molecular modeling studied and experimental results. In order to prove these hypotheses various simplified analogues of these compounds are designed, synthesized, and evaluated as new PKC activators. Some of the simplified analogues demonstrated much high potency to activate PKC, which not only gives some insights how these PKC activators bind with PKC, but also provides the new leads to develop the therapeutic tools to treat the diseases related by PKC.
Export Options
About this article
Cite this article as:
Ma Dawei, Recent Advances in the Discovery of Protein Kinase C Modulators Based on the Structures of Natural Protein Kinase C Activators, Current Medicinal Chemistry 2001; 8 (2) . https://dx.doi.org/10.2174/0929867013373868
DOI https://dx.doi.org/10.2174/0929867013373868 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The p53-p66Shc Apoptotic Pathway is Dispensable for Tumor Suppression whereas the p66Shc-generated Oxidative Stress Initiates Tumorigenesis
Current Pharmaceutical Design Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Prospects of Nanocarriers for Oral Delivery of Bioactives Using Targeting Strategies
Current Pharmaceutical Biotechnology Ewing’s Sarcoma Cancer Stem Cell Targeted Therapy
Current Stem Cell Research & Therapy Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Current Signal Transduction Therapy Natural New Sesquiterpenes: Structural Diversity and Bioactivity
Current Organic Chemistry Non-Human Primate Models for AIDS Vaccine Research
Current Drug Targets - Infectious Disorders Repair and Translesion DNA Polymerases as Anticancer Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Mucoadhesive Nanoparticulate System for Oral Drug Delivery: A Review
Current Drug Therapy Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)
Current Medicinal Chemistry Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets MHC Class I TCR Engineered Anti-Tumor CD4 T Cells: Implications For Cancer Immunotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma
Current Cancer Drug Targets Advances in Targeting Insulin-like Growth Factor Signaling Pathway in Cancer Treatment
Current Pharmaceutical Design Local Activation and Systemic Dysregulation of T Lymphocytes in Sjögren’s Syndrome
Current Pharmaceutical Biotechnology Defective and Excessive Immunities in Pediatric Diseases
Current Pharmaceutical Design Cathelicidins - Natures Attempt at Combinatorial Chemistry
Combinatorial Chemistry & High Throughput Screening Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry